Myomo, Inc. MYO
We take great care to ensure that the data presented and summarized in this overview for MYOMO, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MYO
View all-
Aigh Capital Management LLC Baltimore, MD3.38MShares$20.9 Million8.49% of portfolio
-
Herr Investment Group LLC Austin, TX2.85MShares$17.6 Million0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$7.78 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT900KShares$5.55 Million0.39% of portfolio
-
Essex Investment Management CO LLC Boston, MA794KShares$4.9 Million0.95% of portfolio
-
Clearstead Advisors, LLC Cleveland, OH426KShares$2.63 Million0.04% of portfolio
-
Portolan Capital Management, LLC Boston, MA380KShares$2.34 Million0.18% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA277KShares$1.71 Million0.0% of portfolio
-
Stonepine Capital Management, LLC Bend, OR274KShares$1.69 Million1.43% of portfolio
-
Manatuck Hill Partners, LLC Westport, CT246KShares$1.52 Million0.73% of portfolio
Latest Institutional Activity in MYO
Top Purchases
Top Sells
About MYO
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Insider Transactions at MYO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 13
2025
|
Paul R Gudonis Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
694
+0.07%
|
$0
$0.05 P/Share
|
|
Nov 04
2024
|
Harry Kovelman Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
121
-0.1%
|
$363
$3.7 P/Share
|
|
Oct 03
2024
|
Harry Kovelman Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
121
-0.1%
|
$363
$3.86 P/Share
|
|
Sep 05
2024
|
Harry Kovelman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,700
-5.14%
|
$20,100
$3.76 P/Share
|
|
Sep 04
2024
|
Harry Kovelman Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
139
-0.11%
|
$417
$3.89 P/Share
|
|
Sep 03
2024
|
Harry Kovelman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,029
-1.53%
|
$8,116
$4.01 P/Share
|
|
Aug 05
2024
|
Harry Kovelman Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
128
-0.1%
|
$384
$3.96 P/Share
|
|
Jul 03
2024
|
Harry Kovelman Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
121
-0.09%
|
$242
$2.85 P/Share
|
|
Jul 01
2024
|
Micah Mitchell Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,500
-7.77%
|
$46,500
$3.02 P/Share
|
|
Jul 01
2024
|
Harry Kovelman Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,868
-8.84%
|
$38,604
$3.02 P/Share
|
|
Jul 01
2024
|
David A Henry Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
25,436
-6.3%
|
$76,308
$3.02 P/Share
|
|
Jun 10
2024
|
Micah Mitchell Chief Commercial Officer |
BUY
Payment of exercise price or tax liability
|
Direct |
6,837
+3.31%
|
$20,511
$3.38 P/Share
|
|
Jun 10
2024
|
Harry Kovelman Chief Medical Officer |
BUY
Payment of exercise price or tax liability
|
Direct |
5,347
+3.54%
|
$16,041
$3.38 P/Share
|
|
Jun 10
2024
|
David A Henry Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,620
-2.56%
|
$31,860
$3.38 P/Share
|
|
Jun 09
2024
|
Micah Mitchell Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,717
+0.92%
|
-
|
|
Jun 09
2024
|
David A Henry Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,012
+0.78%
|
-
|
|
Jun 09
2024
|
Harry Kovelman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,235
+0.98%
|
-
|
|
Jun 09
2024
|
Paul R Gudonis Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,024
+0.59%
|
-
|
|
Jun 05
2024
|
Micah Mitchell Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+19.5%
|
-
|
|
Jun 05
2024
|
David A Henry Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+14.45%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 363K shares |
|---|---|
| Payment of exercise price or tax liability | 12.2K shares |
| Exercise of conversion of derivative security | 12.7K shares |
| Open market or private purchase | 100K shares |
| Payment of exercise price or tax liability | 85.3K shares |
|---|---|
| Open market or private sale | 44.2K shares |